Inhalations Sciences: US patent extended until 2034
(Stockholm August 16, 2021) Inhalation Sciences’ US patent protection on its unique aerosol generation system PreciseInhale® has been extended until 2034. Increasing global presence has been a key strategy for ISAB in 2021, with the US as a priority market.
ISAB’s first US patent application was submitted on July 16, 2014, when it was approved up until December 1, 2020 under the number 10,850,289. The patent has now been extended and is valid until August 21, 2034.
PreciseInhale® delivers exceptionally precise preclinical data that significantly reduces risk in inhaled drug development. It is currently being trialled for clinical use in humans.
ISAB CEO Manoush Masarrat: “The US is a major market with a dynamic, innovative sector and being a key market for ISAB, we have increased our commercial efforts there heavily during the first half of 2021. This patent extension, together with the ongoing clinical validation of PreciseInhale®, will enable us to offer customers in the US a unique aerosol research platform throughout the coming decades.”
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
Tags: